Alpha Cancer Technologies is a private clinical-stage biotechnology company developing platforms in immuno-oncology, radiopharmaceuticals, and immunomodulation. Its programs are built around a patented recombinant human alpha fetoprotein platform, or ACT-101, with development work spanning cancer and autoimmune disease applications. The company’s website describes IND-enabling work in radiopharmaceutical and immuno-oncology programs and a Phase II-ready immunomodulation program in myasthenia gravis.